ABIVAX Société Anonyme (ABVX)

Market Cap	5.36B
Revenue (ttm)	11.44M
Net Income (ttm)	-200.76M
Shares Out	63.42M
EPS (ttm)	-3.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,357
Open	69.77
Previous Close	70.84
Day's Range	69.67 - 71.32
52-Week Range	4.77 - 72.90
Beta	1.53
Analysts	Buy
Price Target	74.86 (+4.92%)
Earnings Date	Aug 11, 2025

About ORTX

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: ABVX
• Website: https://www.abivax.com

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is $74.86, which is an increase of 4.92% from the latest price.

Price Target

$74.86

(4.92% upside)

Analyst Consensus: Buy